Report

QuickView: Focused on HIV immunotherapy and Ebola

GeoVax continues to focus on advancing both its HIV immunotherapy programme and Ebola vaccines, which will require additional funding. Further development of the GOVX-B11 preventative HIV vaccine remains under consideration by the US NIH, although a large Phase IIb trial in 2015 now seems unlikely as HVTN reconsiders the merits of adding a protein boost. The exercise of certain warrants has increased cash to c $1.7m.
Underlying
Provider
Edison Investment Research
Edison Investment Research

Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.

.

Other Reports on these Companies
Other Reports from Edison Investment Research

ResearchPool Subscriptions

Get the most out of your insights

Get in touch